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1. Introduction 
Osteoporosis (OP) is the most widely spread metabolic osteopathy in the Western world, 
and is defined as a generalised state of the skeletal structure, characterised by a low bone 
mass and microarchitectural alterations, with an increase in bone fragility and risk of 
fracture (1). OP is now considered as an evolutive disorder affecting both the mineral and 
organic components leading to a progressive reduction in bone density, due to an imbalance 
in the regulation of hormones, which normally regulates the skeletal tissues (2). There are 
numerous classifications of OP in existence based on its pathogenesis , age of onset, 
association with other pathologies and pharmacological treatment or skeletal districts 
involved. Alongside primary OP is the heterogeneous group of secondary OP, which is 
either the consequence of the core disease or of the use of drugs. HIV infection has been 
shown to play an important role in the development of OP (3) and high prevalence of both 
osteopenia (OPe) and OP have been reported in subjects with chronic HIV infection (4). Loss 
of body weight, low body mass index (BMI) and diminished functional capacity are among 
some of the risk factors which, to a large extent, contribute to the loss of bone tissues in 
subjects suffering from chronic HIV infection (2-8).Furthermore, the drugs used to treat 
HIV+ patients can also interfere with bone metabolism and contribute to loss of bone mass 
(16). A reduction in bone mineral density (BMD) was observed in both HIV+ patients with 
hypogonadism and in those without (9-11). OP seems to be most frequently observed in 
subjects undergoing intense antiretroviral therapy, however, the mechanism by which 
antiretroviral treatments interfere with bone metabolism has not yet been clearly 
demonstrated. 
The success of highly active antiretroviral therapy (HAART) has dramatically increased the 
life expectancy of HIV+ patients in the developed world, however, their use has been 
associated with a range of side effects and complications. As people with HIV now live 
longer, bone disease is among the metabolic complications presenting physicians with new 
challenges in the management of the HIV+ patients (12). Although, OP is the most common 
bone disease described in HIV, but osteomalacia, usually in association with Fanconi’s 
syndrome or in patients treated with tenofovir, is also reported (15). 
The reduction in bone mass and the disruption of bone architecture increases the risk of 
bone fracture leading to disability, morbidity and mortality especially in the older 
population. One in two women and one in five men over the age of 50 years will suffer a 
fracture due to OP during their lifetime (13). There are concerns that as the HIV+ population 
ages, increased rates of bone loss may give rise to an ‘epidemic’ of fragility fractures (17). 
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Evidence is needed to inform judicious use of bone protective agents so that this situation 
can be avoided.  
2. Does HIV cause low bone mineral density? 
Validated risk factors for reduced BMD and fragility fracture are well established for the 
general population (19). They include,old age, low BMI, previous fragility fracture, low 
BMD at the femoral neck, parental history of hip fracture; glucocorticoid exposure; 
rheumatoid arthritis; current smoking; alcohol consumption of more than 3 units per day; 
hypogonadism, including post-menopausal status in women; prolonged immobility; 
malabsorption and liver cirrhosis (20). In addition, other well reported associations exist, 
including vitamin D deficiency, opiate (21) and other substance dependence (22) and the use 
of selective serotonin uptake inhibitor (SSRI) antidepressants (23). Some of the risk factors 
for OP described in the general population are also prevalent in people with HIV infection. 
The HIV+ population also has high rates of vitamin D insufficiency, high prevalence of 
smoking, alcohol abuse and injection drug use, opiate use and depression requiring SSRI 
treatment that are also risk factors for OP (25). Patients presenting late in their illness with 
AIDS usually have a low BMI. Immune reconstitution inflammatory syndrome (IRIS), which 
arises when HAART-associated immune reconstitution leads to an unmasking or worsening 
of features of infections such as tuberculosis, may require prolonged courses of 
glucocorticoid therapy (26), as may treatment of malignancies. Chronic diarrhoea resulting 
in malabsorption and nutritional deficiency can occur secondary to opportunistic infections 
or HIV directly. Androgen deficiency was common in the pre-HAART era in men 
presenting with AIDS-associated wasting (27) and is still seen in HIV-infected men on 
HAART presenting with weight loss (28). Low testosterone levels have also been reported in 
association with intravenous drug use (29). Of note, menstrual abnormalities are not more 
prevalent in HIV-infected women compared with non-infected women (30). There are 
growing numbers of studies reporting an increased prevalence of vitamin D deficiency in 
HIV-positive individuals compared to HIV-negative controls. Other studies have also 
demonstrated reduced 25-hydroxyvitamin D serum levels in HIV+ individuals taking 
HAART compared to age- and sex-matched HAART-naïve HIV+ individuals, with non-
nucleoside reverse transcriptase inhibitor (NNRTI) use and, moreover, cumulative exposure 
to efavirenz (but not nevirapine) being specifically implicated. Considering the high 
prevalence of the above risk factors in the HIV-infected population, it could be argued that 
the increased prevalence of decreased BMD in HIV-positive individuals is not surprising. It 
is very challenging, however, to separate HIV-specific factors from the confounding effect of 
traditional risk factors which are over-represented in the HIV-positive population. 
HIV-specific risk factors. As well as establishing the contribution of known OP risk factors 
within the HIV-positive population, cross-sectional and longitudinal studies have also 
related changes in BMD to HIV-specific factors, for example duration of HIV infection, HIV 
viral load and CD4 cell count, to determine whether these represent independent risk 
factors for reduced BMD in the HIV-positive population and consequently whether HIV 
infection is a risk factor for reduced BMD in its own right. The extent of the rise in CD4 cell 
count was directly proportional to the BMD increase at the lumbar spine in one longitudinal 
study of patients on HAART (31). Similar findings were seen in another longitudinal study, 
although without adjustment for simultaneous rise in BMI (28). The BMD increase in these 
two studies was also independently associated with having an undetectable HIV viral load. 
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In support of these findings a high HIV viral load at the time of assessment by Dual Energy 
X-Ray Absorptiometry (DXA) correlated positively with reduced BMD in one cross-
sectional study (32), although neither high HIV viral load nor low CD4 count were 
associated with reduced BMD in other studies (33). A low nadir CD4 cell count has been 
shown to be an independent risk factor for both reduced BMD and increased fracture 
incidence after adjustment for BMI (34). Time from date of diagnosis and prolonged 
exposure to unsuppressed HIV was also found to be an independent risk factor for loss of 
BMD in three studies (33).  
3. HIV-1 infection has direct influence on bone turnover 
The mechanical competence of bone is maintained by the process of bone remodelling, 
which consists of the removal of old bone by osteoclasts and its subsequent replacement 
with new bone by osteoblasts. In young adult skeleton, the amounts of bone resorbed and 
formed are similar, thus maintaining bone mass. Bone loss may occur in OP as a result of 
increased resorption, decreased formation or a combination of the two. In age-related bone 
loss in women, both mechanisms play a role, whereas in men, reduced bone formation is the 
predominant changes (49).The cellular mechanisms underlying bone loss in HIV+ 
individuals are not well defined, although in one study, reduced bone formation and 
turnover were reported in iliac crest biopsies (49,50). The association between chronic 
inflammatory conditions and OP is well documented and receptor activator of NFkB ligand 
(RANKL), the key mediator of osteoclast activity, is produced by activated T cells (46). Even 
in the asymptomatic phase of HIV infection, levels of inflammatory cytokines such as 
interleukin-1 (IL-1), IL-6 and tumor necrosis factor alpha (TNFa) are increased, and these 
cytokines also stimulate bone resorption (51). TNFa has also been shown to mediate 
apoptosis of human osteoblasts in response to HIV gp120 (52). Studies recently reported that 
levels of RANKL were higher in HIV-infected men and correlated with reduced BMD. 
Osteoblast and osteoclast function is influenced by a number of factors during HIV-1 
infection, including pro-inflammatory cytokines such as TNF-a, expression of receptor of 
activated NF-kB ligand (RANKL) and osteoprotegerin (OPG), vitamin D and calcium 
metabolism and hormone levels (36). Although there is not convincing evidence that 
osteoblasts or osteoclasts are directly infected, their function may be modulated by a variety 
of HIV proteins. The HIV envelope glycoprotein, gp 120, can induce TNF-a dependent 
apoptosis of osteoblast cell lines or primary cells (37); however many HIV-mediated effects 
occur without affecting cell viability. Inflammatory conditions modify bone metabolism, 
including a variety of factors released by T-cells and macrophages such as TNF-a, IFN-c, IL-
4, macrophage inflammation protein-1 (MIP-1) and RANKL. Markers of bone resorption in 
advanced HIV infection correlate with TNF-a levels (38). During HIV infection the cytokine 
profile favors TNF-a expression and increased viral replication, whilst there is a shift 
towards a TH2 cytokine balance, with decreased production of IFN-c (34). In turn enhanced 
TNF-a levels increases expression of RANKL with resulting stimulation of osteoclast activity 
(39). A number of studies suggest HIV proteins can shift the OPG/RANKL ratio in favour of 
RANKL-mediated osteoclastic activation (40). HIV Vpr (viral protein R), a factor needed for 
viral replication being required for the nuclear import of the HIV-1 pre-integration complex, 
up-regulates RANKL, potentiating glucocorticoid-induced stimulation of RANKL (41). 
gp120 also stimulates RANKL (42). ARV naïve HIV-positive individuals have increased 
serum RANKL levels and reduced OPG/RANKL ratios, which correlate negatively with the  
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HIV viral load and the Z-score obtained by densitometry (43). RANKL is not only produced 
by osteoblasts but also by activated T-cells, which represent a likely source of enhanced 
RANKL expression in light of their increased numbers during HIV infection. Although the 
natural inhibitor of RANKL, OPG, is also enhanced in the serum of ARV naïve individuals, 
increased binding of OPG to another factor up regulated by HIV, TNF-related apoptosis- 
inducing ligand (TRAIL), in preference to RANKL, limits its availability to inhibit osteoclast 
activation by RANKL (44). RANK (receptor of activated NF-kB) signalling via tumour 
necrosis factor receptor-associated factor 6 (TRAF-6) facilitates nuclear factor kappa B (NF-
kB) activation and phosphorylates (activates) c-Jun NH2- terminal kinase (JNK) 1 and Akt 
facilitating osteoclastogenesis. gp120 may also stimulate RANKL via activation of 
extracellular signal-regulated kinase (ERK) signaling. Nevertheless the specific RANK 
signaling events activated by HIV-1 are still being delineated. RANKL appears to limit the 
susceptibility of mitochondria to oxidative stress induced dysfunction in response to 
nucleoside reverse transcriptase inhibitors (NRTIs) by mechanisms that do not involve 
alterations in levels of mitochondrial superoxide dismutase (SOD) (45). These observations, 
in macrophage cell lines, if replicated in osteoclasts, may suggest a potential mechanism for 
enhanced osteoclastogenesis in response to RANKL could therefore be maintenance of 
mitochondrial metabolism despite increasing cell stress and therefore maintenance of 
osteoclast viability and prevention of apoptotic death (46). HIV proteins gp120 and the gag 
structural protein p55 suppress osteoblast activity in cell lines with up-regulation of the 
transcription factor RUNX-2 and decreased release of RANKL. p55 also suppresses 
osteoblast differentiation from mesenchymal stem cells (47).  
4. Does HAART increase the risk of osteoporosis? 
Protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) have been 
the agents most widely investigated as causes for reduced BMD in HIV+ populations. 
However, consistent evidence for their effects is lacking and it is increasingly recognized 
that these may be drug rather than class-specific (48). Potential mechanisms by which 
antiretroviral might negatively affect BMD have been identified in vitro. Some PIs have been 
shown to inhibit osteogenesis and increase osteoclastogenesis, whereas others may decrease 
bone loss (53). Metabolic and morphologic changes have been described in patients with 
HIV infection receiving antiretroviral therapy (ART), including alterations in body fat 
distribution, dyslipidemia, lactic acidosis, glucose metabolism abnormalities, and bone 
metabolism abnormalities. The etiologies of these disorders are being investigated and are 
likely to be multifactorial. It is clear, however, that ART plays a significant role in these 
alterations. 
5. Pathophysiology of osteoporosis in HIV patients 
In the light of these facts, we set out to determine the incidence of OPe and OP, within a 
population of subjects suffering from chronic HIV infection, by calculating the biochemical 
parameters using the ultrasonic densitometer. The Quantitative Ultrasound Densitometry 
(QUS) was chosen for the fact that this exam enabled us to predict the risk of fractures, also 
for the vertebrae, comparable to the DEXA method (56-58), in addition to its low cost and 
feasibility. This study consisted of 26 HIV+ patients (mean age 47.9 ± 12.8), with a average 
duration of infection equal to 6.7 ± 4.8 years and seropositive duration ranging from 6 
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months to 16 years. This group of patients did not exhibit any associated diseases, while the 
BMI was equal to 24.82±1.45. No other type of pharmacological treatment was introduced 
other than the one for HIV infection. In this group of patients, 6 exhibited illnesses 
associated with HIV, such as: pneumocystis carinii infection, hepatocellular carcinoma, 
tuberculosis, cerebral neoplasia and HIV-related encephalitis. From our samples, 4 belonged 
to class C under the CDC classification (Centers for Disease Control – USA; 23) (59). 
The aim of our study was to determine has been to observe whether the presence of 
seropositivity for HIV could constitute to the development of OPe and/or overt OP. 
Meanwhile, our group of patients fell within the age bracket well below the limit for both 
post-menopausal and senile OP, with a superimposable average age for either sex. The 
different aspects evident at the bone level during the course of HIV infection stress that , in 
the various forms of genesis the IPs (Protease inhibitors (PIs) seem to play a causal 
predominant role. Other attributable factors are in play, like the possible interference of 
hormonal factors (behavioural and/or nutritional) directly correlated with the state of 
infection, but also the dysmetabolic effects of the antiretroviral drugs depending on the 
mechanism and the time involved. The protocols of the HAART therapy on the hand lead 
with a decisive improvement in the life expectancy and quality of life of HIV+ patients, but 
expose to toxic effects, which generally become more frequent and severe as the treatment is 
prolonged, and may take effect within diverse metabolic areas. As far as the skeletal 
structure is concerned, such effects can seriously impair the status of bone metabolism with 
pathological pictures of variable graveness, ranging from OPe to osteonecrosis (with a 
higher risk of developing pathological fractures). It is of extreme importance to have one or 
more of the instruments to safely and easily individualise the alterations of bone resistance 
readily available for diagnostic procedures aimed at various aspects of the disease and the 
adverse reactions of the antiretroviral therapy, before they advance into significant clinical 
events. In fact, a prompt diagnosis can allow for the implementation of more efficient 
therapeutic and prophylactic measures. Bone resistance must be considered, in a modern 
sense, as a fundamental characteristic of the bones themselves, which contribute to 
quantitative (bone density) and qualitative factors (structural properties, biomechanical 
properties, bone turnover). Our study also included an ultrasonometric bone assessment 
and biochemical assessment – in terms of neoformation marker and bone resorption 
markers. Motivations which have led us to use the ultrasonic densitometer to calculate the 
variations of bone resistance in the population in question were based on the grounds of 
employing a procedure which was safe and non invasive. This decision was also based on 
the possibility of obtaining accurate information on all the factors influencing bone 
resistance (biomechanical competence and elements associated to bone quality). In the 
course of our study, the ultrasonic densitometer also proved to be a highly sensitive 
diagnostic safeguard, allowing us to individualise an elevated incidence of cases of OPe/OP 
in HIV+ subjects. Analysis of the ultrasonometric parameters according to sex does not 
show significant variations, except for the broadband ultrasound attenuation (BUA), which 
seems to be significantly lower in females with respect to males. Significant variations can 
also be observed in relation to the duration of HIV infection, with ultrasonometric values 
highlighting its inclination towards OPe/OP with an increase in the number of years of 
infection-disease. Significant, indeed, is the reduction in the values of BMD relative to the 
duration of infection; proving the hypothesis that HIV inhibits osteoblastic activities and 
triggers osteoclastic activities, resulting in a negative skeletal balance, with an annual 
reduction in BMD values equal to approximately 1%. As for the dosage of sieric osteocalcin, 
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particularly the bone neoformation index, the data obtained does not allow for the complete 
explanation of the significance of the diagnosis, however, it does highlight the elevated 
sieric concentration in women after about 10-12 years of seropositivity, conferming the 
ultrasonometric results showing the presence of the aggressive processes of bone 
mineralisation. The assessment of other bone turnover markers does not reveal any 
significant variations – in terms of resorption marker – in subjects belonging to diverse 
classes under the CDC classification, with the exception of d-PYR in the group with the most 
serious conditions: this marker showed an unexpected lower mean level compared to the 
groups with patients in less aggressive situations. Although the results obtained from our 
study does not enable us to reach a definitive conclusion regarding the origin of the pictures 
of alterated bone mineralisation during the course of HIV infection, it does emphasise the 
considerable incidence, and destined to increase, thanks to the ever improving life 
expectancy as a result of more efficient antiretroviral therapies which are better tolerated by 
the patients. This problem presents a particularly serious connotation in younger subjects 
where the consequence of a chronic reduction in bone quality and quantity could result in 
irreversible disability. Bear in mind that it is, therefore, advisable to predispose accurate 
protocols when monitoring the skeletal development in these patients, based on the use of 
biochemical and instrumental research. Each patient should be followed with an individual 
programme, appropriately prepared based on age and personal characteristics, along with 
regular physical activities aimed at strengthening the skeletal muscles. It should also include 
a healthy diet, with particular reference to daily intakes of calcium and Vitamin D (60). 
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